GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rosetta Genomics Ltd (OTCPK:ROSGQ) » Definitions » Cash per Share

Rosetta Genomics (Rosetta Genomics) Cash per Share : $0.51 (As of Jun. 2017)


View and export this data going back to 2007. Start your Free Trial

What is Rosetta Genomics Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Rosetta Genomics's Cash per Share for the quarter that ended in Jun. 2017 was $0.51.

Rosetta Genomics Cash per Share Historical Data

The historical data trend for Rosetta Genomics's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rosetta Genomics Cash per Share Chart

Rosetta Genomics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 40.63 19.23 8.09 7.28 3.34

Rosetta Genomics Quarterly Data
Dec10 Mar11 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Jun17
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.85 4.63 3.12 3.34 0.51

Rosetta Genomics Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Rosetta Genomics's Cash per Share for the fiscal year that ended in Dec. 2016 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=6.163/1.84
=3.34

Rosetta Genomics's Cash per Share for the quarter that ended in Jun. 2017 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=1.325/2.59
=0.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rosetta Genomics  (OTCPK:ROSGQ) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Rosetta Genomics Cash per Share Related Terms

Thank you for viewing the detailed overview of Rosetta Genomics's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Rosetta Genomics (Rosetta Genomics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rosetta Genomics Ltd (OTCPK:ROSGQ) » Definitions » Cash per Share
Comparable Companies
BOM:526504 TSXV:MBI.H TEAR TSXV:AVCR NGM:LIFE B BOM:526546 BOM:541299 ASX:CTE TSXV:TELO ASX:LSH IDTA XSAT:ALPH BOM:526301 ABMC XLRM WAR:BMX XKRX:271850 WAR:IGN BOM:516110 SGX:505
Traded in Other Exchanges
N/A
Address
10 Plaut Street, Science Park, Rehovot, ISR, 76706
Website
http://www.rosettagenomics.com
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.
Executives
Sabby Management, Llc 10 percent owner 115 HIDDEN HILLS DR, SPICEWOOD TX 78669
Sabby Healthcare Volatility Master Fund, Ltd. 10 percent owner C/O SABBY MANAGEMENT, LLC, 10 MOUNTAINVIEW ROAD, SUITE 205, UPPER SADDLE RIVER NJ 07458